Clinical Trial Update: A Study of Venetoclax in Combination With Low Dose Cytarabine Versus Low Dose Cytarabine Alone in Treatment Naive Patients With Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy [Phase 3]

View source ↗

Summary

A Phase 3 study comparing venetoclax plus low-dose cytarabine versus low-dose cytarabine alone in treatment-naive acute myeloid leukemia patients ineligible for…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Cytarabine (Low-Dose) (cytarabine)
• Venetoclax (venetoclax)

Snippet

Sponsor: AbbVie | Conditions: Acute Myeloid Leukemia (AML) | Phase 3 | Status: COMPLETED | Results posted: 2020-02-28